Eris Lifesciences Ltd - 540596 - Corporate Presentation
Dear Sir/Madam, Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the corporate presentation made by the Company. Eris Lifesciences Ltd - 540596 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24(A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Secretarial Compliance Report duly issued by the Practicing Company Secretary for the financial year ended March 31, 2023. This is for your information and records. Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is to inform that the transcript of the Analyst and Investor call which was held after the announcement of financial results for the quarter and year ended 31st March 2023 is available on our website URL https://eris.co.in/financials/ (File name: Transcript of the Analyst and Investor Conference Call Q4FY23).
Buy Eris Lifesciences; target of Rs 780: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 780 in its research report dated May 18, 2023. Eris Lifesciences Ltd - 540596 - DISCLOSURES OF RELATED PARTY TRANSACTIONS UNDER REGULATION 23(9)
Dear Sir/Madam, Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed by SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half-year ended commencing from 1st October, 2022 to 31st March, 2023. Kindly take note the same. Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Dear Sir/Madam, In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we wish to inform you that the Audio Recording of the Earnings Conference Call in connection with the Consolidated and Standalone Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023, held on May 17, 2023, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/ (File name: Q4 FY23 Earnings Call Recording) Eris Lifesciences standalone Q4 net marginally up at 88 crore
Consolidated expenses were up 39% for the year, impacting profitability Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Credit Rating
In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, if any, we hereby notify the assignment of rating to the Company by India Rating & Research which appears at the following link: Link: India Rating Press Release